TRANSGENE

TNG
Real-time Euronext Paris - 11:35 2022-12-01 am EST
1.840 EUR +1.10%

Turn to zoom
Prev.1.82000000
Open1.81000000
High1.84000000
Low1.81000000
Volume24 768
Latest news
11/14
11/03
11/02
11/02
Chart TRANSGENE
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishBearish
Resistance1,882,122,22
Spread/Res.-2,1%-13%-17%
Spread/Supp.1,9%9,5%15%
Support1,811,681,60
Financials
Sales 2022 12,5 M 12,8 M 12,8 M
Net income 2022 -31,8 M -32,8 M -32,8 M
Net cash 2022 39,1 M 40,3 M 40,3 M
P/E ratio 2022 -5,69x
Yield 2022 -
Capitalization 181 M 187 M 187 M
EV / Sales 2022 11,4x
EV / Sales 2023 8,30x
Nbr of Employees 143
Free-Float 100%
Company
Transgene, part of Institut Mrieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly...
Sector :
Bio Therapeutic Drugs
Calendar :
2023-03-22 Earnings Release
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,82 €
Average target price 3,95 €
Spread / Average Target 117%